1-ethanesulfonyl-4-isopropyl-piperazine | 98952-33-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-ethanesulfonyl-4-isopropyl-piperazine
• 英文别名: 1-Aethansulfonyl-4-isopropyl-piperazin；1-(Ethylsulfonyl)-4-isopropylpiperazine；1-ethylsulfonyl-4-propan-2-ylpiperazine
• CAS: 98952-33-1
• 化学式: C₉H₂₀N₂O₂S
• 分子量: 220.336
• InChiKey: BZPPGBSDRSQMPE-UHFFFAOYSA-N

物化性质

• 沸点：
  129-130 °C(Press: 0.7 Torr)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  49
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-异丙基哌嗪 、 乙基磺酰氯 在 乙醚 作用下， 生成 1-ethanesulfonyl-4-isopropyl-piperazine
  参考文献：
  名称：

  1-alkylsulfonyl-4-alkyl piperazines

  摘要：

  公开号：

  US02507408A1

文献信息

• MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
  申请人：Weinstein David S.

  公开号：US20090075995A1

  公开（公告）日：2009-03-19

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including inflammatory and immune diseases, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; A is a 5- to 8-membered carbocyclic ring or a 5- to 8-membered heterocyclic ring; B is a cycloalkyl, cycloalkenyl, aryl, heterocyclo, or heteroaryl ring, wherein each ring is fused to the A ring on adjacent atoms and optionally substituted by one to four groups which are the same or different and are independently selected from R 5 , R 6 , R 7 , and R 8 ; J 1 , J 2 , and J 3 are at each occurrence the same or different and are independently -A 1 QA 2 -; Q is a bond, O, S, S(O), or S(O) 2 ; A 1 and A 2 are the same or different and are at each occurrence independently selected from a bond, C 1-3 alkylene, substituted C 1-3 alkylene, C 2-4 alkenylene, and substituted C 2-4 alkenylene, provided that A 1 and A 2 are chosen so that ring A is a 5- to 8-membered carbocyclic or heterocyclic ring; R 1 to R 11 are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.

  提供了一系列新颖的非甾体化合物，这些化合物在治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病中很有用，包括炎性和免疫疾病，具有以下结构式（I）： 其对应的光学异构体、对映异构体或互变异构体，或其前药酯，或其药用可接受盐，其中： Z是杂环或杂芳基； A是一个5至8成员的碳环或一个5至8成员的杂环； B是一个环烷基、环烯基、芳基、杂环或杂芳基环，其中每个环都与A环上的相邻原子融合，并且可以选择性地被一个到四个独立选自R5、R6、R7和R8的相同或不同的组取代； J1、J2和J3每次出现时相同或不同，独立地选自-A1QA2-；Q是键、O、S、S(O)或S(O)2；A1和A2相同或不同，每次出现时独立地选自键、C1-3烷基、取代的C1-3烷基、C2-4烯基和取代的C2-4烯基，前提是A1和A2的选择使得环A是一个5至8成员的碳环或杂环； R1至R11如本文所述定义。 还提供了使用这些化合物的药物组合物和治疗炎性疾病、免疫相关疾病、肥胖和糖尿病的方法。
• TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
  申请人：NORTHWEST UNIVERSITY

  公开号：US20170267718A1

  公开（公告）日：2017-09-21

  Provided are a tripeptide compound, a preparation method therefor, and an application thereof. The structure of the related compound is represented by formula (I). The provided compound has angiotensin converting enzyme inhibiting bioactivity, and the compound and a pharmaceutical composition thereof play a role in preventing and treating hypertension and other cardiocerebral vascular system diseases.

  提供了一种三肽化合物，其制备方法和应用。相关化合物的结构由式（I）表示。提供的化合物具有抑制血管紧张素转换酶的生物活性，该化合物及其药物组成对预防和治疗高血压和其他心脑血管系统疾病起着作用。
• Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors
  申请人：Arrien Pharmaceuticals LLC

  公开号：US20160090382A1

  公开（公告）日：2016-03-31

  Compounds according to Formulas I, IA or IB: to pharmaceutically acceptable composition, salts thereof, their synthesis and their use as SIK2 inhibitors including such compounds and methods of using said compounds in the treatment of various diseases and/or disorders such as cancer, stroke, cardiovascular, obesity and type II diabetes.

  按照I、IA或IB公式制备的化合物：制备药用可接受的组合物、其盐、它们的合成以及它们作为SIK2抑制剂的用途，包括这些化合物和使用这些化合物治疗各种疾病和/或疾病的方法，如癌症、中风、心血管疾病、肥胖和2型糖尿病。
• [EN] PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF<br/>[FR] COMPOSÉ PYRAZOLOPYRIDAZINONE, COMPOSITION PHARMACEUTIQUE LE CONTENANT ET SON UTILISATION<br/>[ZH] 吡唑并哒嗪酮化合物、其药物组合物及其用途
  申请人：BROADENBIO CO LTD

  公开号：WO2022095904A1

  公开（公告）日：2022-05-12

  本申请提供了如式(I)所示的化合物、含该化合物的药物组合物及其用途。本申请的式(I)化合物，具有良好的抑制HPK1活性的作用。
• 1-alkylsulfonyl-4-alkyl piperazines
  申请人：RHONE POULENC SA

  公开号：US02507408A1

  公开（公告）日：1950-05-09